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Objectives  Our objective was to evaluate the degree of tracking for serum levels of 25-25	
hydroxyvitamin D [25(OH)D] over time, by using data from three previously conducted 26	
surveys of the Tromsø study collected in the years 1994/1995 (Tromsø 4), 2007/2008 (Tromsø 27	
6) and 2015/2016 (Tromsø 7).  28	
Subjects and Methods  Subjects with valid 25(OH)D measurements in all three surveys were 29	
included. 25(OH)D z-scores were used to adjust for seasonal variation. Z-scores and sextiles 30	
were used to illustrate tracking of 25(OH)D.  31	
Results  1,702 subjects (572 males, 1,130 females) fulfilled the inclusion criteria. Median (5th, 32	
95th percentiles) age for these subjects was 55 (33, 65) years in Tromsø 4, and mean (SD) 33	
25(OH)D levels were 57 (18) nmol/L, 59 (19) nmol/L and 72 (21) nmol/L for Tromsø 4, 34	
Tromsø 6, and Tromsø 7, respectively. There was significant tracking of serum 25(OH)D over 35	
the 21 years period between the surveys of the Tromsø study. The correlation coefficient r 36	
between 25(OH)D z-scores from Tromsø 4 and Tromsø 6 was 0.40, and declined to 0.29 for 37	
the correlation between Tromsø 4 and Tromsø 7. 26 % of the subjects in the lowest 25(OH)D 38	
z-score sextile in Tromsø 4 were in the three highest sextiles of 25(OH)D in Tromsø 7. 39	
Similarly, 35 % of those in the highest sextile in Tromsø 4, were in the lowest three sextiles in 40	
Tromsø 7.  41	
Conclusion  The degree of tracking for serum 25(OH)D declines over time, and the use of a 42	
single serum 25(OH)D measurement as an indicator of the vitamin D status is questionable if 43	









The importance of vitamin D for skeletomuscular health is well established [1, 2]. The 51	
discovery of vitamin D receptors in almost all tissues of the body, also in those not related to 52	
calcium or bone metabolism [2], lead to discussions about its potential role in multiple heath 53	
related issues. Following this discovery there have been many studies published on the 54	
association between vitamin D status and an array of non-calcemic medical conditions, such 55	
as cardiovascular disease, cancer, obesity, depression and dementia [3]. Currently, serum 56	
levels of 25-hydroxyvitamin D [25(OH)D] are viewed as the standard method to evaluate a 57	
subject’s vitamin D status and most often this vitamin D status assessment is based on a single 58	
measurement [4, 5]. 59	
     In recent years there is new evidence that vitamin D levels are not only dependent on sun 60	
exposure and diet [1], but are also to a significant degree determined genetically [6, 7]. This, 61	
and vitamin D’s possible association with numerous diseases, amplifies the value of being 62	
able to predict vitamin D levels in an individual over time. Preferably, this prediction would 63	
be based on a single or a few serum values, and enable an appraisal of a subject’s vitamin D 64	
status over time. This constancy of 25(OH)D level in a specific individual over a longer 65	
period of time is referred to as tracking. 66	
     In a previous article from 2010, our research group confirmed tracking of serum 25(OH)D 67	
within individuals based on samples taken 13 years apart  in 2,668 subjects. This was based 68	
on observations from the Tromsø study – an observational, longitudinal study, which is 69	
repeated on regular intervals in the form of surveys, examinations and collection of biological 70	
data from the population in the Tromsø municipality [8]. Since then, several papers have been 71	
published regarding tracking of 25(OH)D [9-21]. However, these studies have been 72	
considerably smaller, and/or have had much shorter observation time, or have focused on 73	
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population subgroups like pregnant women [11] or children/adolescents [17, 18, 20]. In 74	
general, they have confirmed our original observation of a high degree of tracking, as could 75	
be expected with a shorter observation time.  76	
     The seventh survey in the Tromsø study was performed in 2015/2016 and a considerable 77	
number of those included in our original tracking publication also participated in this survey. 78	
We therefore had the opportunity to evaluate the tracking of 25(OH)D over a 21 years time 79	
period.  80	
 81	
Materials and method 82	
 83	
The Tromsø survey is a longitudinal, observational population study conducted by the 84	
University of Tromsø – The Arctic University of Norway, and the Norwegian National Heath 85	
Screening Service. Initiated in mid-1970 as a means of mapping cardiovascular disease in 86	
north Norwegian males, it has since evolved to include a large portion of Tromsø municipality 87	
inhabitants of both sexes and with a wide range of age groups [22, 23]. The focus has also 88	
shifted; from the narrow emphasis on cardiovascular disease, to a multi-focus study with 89	
detailed data gathered on lifestyle, and a wide range of health issues [23]. The study has been 90	
repeated with regular intervals and recently finished its seventh survey in 2015/2016. In the 91	
present study we have used data from the fourth, sixth and seventh surveys:   92	
- The fourth survey (“Tromsø 4”) was performed in 1994/1995 and invited all citizens 93	
aged 25 years or older living in Tromsø municipality (n = 37,558) of whom 27,158 94	
subjects participated in the first phase of the survey. Furthermore, all men aged 55 – 95	
74 years, all women aged 50 – 74 years and 5 – 8 % random samples of the other age 96	
groups < 85 years were invited to a second visit with more extensive examinations. 97	
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Among 10,542 eligible subjects 7,965 attended this second phase, and 7,156 (2,269 98	
smokers and 4,887 non-smokers) had serum 25(OH)D measured.  99	
- The sixth survey (“Tromsø 6”) was performed in 2007/2008. All who had participated 100	
in the second phase of Tromsø 4, a 10 % random sample of those 20 – 39 years old, all 101	
subjects 40 – 42 or 60 – 87 years old, and a 40 % random sample of those 43-59 years 102	
old were invited. Among the 19,762 subjects invited, 12,984 subjects attended and 103	
12,444 (2,389 smokers and 10,055 non-smokers) had serum 25(OH)D measured. 104	
- The seventh survey (“Tromsø 7”) was performed in 2015/2016 and all citizens aged 105	
40 years or above living in Tromsø municipality (n = 32,591) were invited, among 106	
whom 21,084 participated and 20,720 (2,878 smokers and 17,842 non-smokers) had 107	
serum 25(OH)D measured.  108	
     The Tromsø surveys are binary in design, with a questionnaire part followed by physical 109	
examination and blood sampling. The details regarding the questionnaires and examinations 110	
can be found on http://tromsoundersokelsen.uit.no/tromso/ (May-November, 2019). The 111	
surveys contain information on age, sex, smoking habits, medication, use of cod liver oil and 112	
vitamin D supplements.  113	
     The wording in the questionnaires regarding cod liver oil and vitamin D supplements 114	
differed between the surveys. In Tromsø 4 the cod liver oil question was: “Have you used cod 115	
liver oil or fish oil capsules during the last 14 days (“yes”/”no”)?”. In Tromsø 6 and Tromsø 7 116	
the corresponding question was “Do you use cod liver oil or cod liver oil capsules?”. The 117	
answer options in Tromsø 6 were “yes, daily”/”sometimes”/”no”, and in Tromsø 7 118	
“no”/”sometimes”/”daily during the winter season”/”daily”. In Tromsø 4 the vitamin D 119	
supplement question was “Have you used vitamin D supplements during the last 14 days?” 120	
and in Tromsø 7 “Do you use vitamin supplements with vitamin D?” with the same answer 121	
6	
	
options as for cod liver oil. Vitamin D supplements were not specifically asked for in Tromsø 122	
6.  123	
     The Tromsø 6 and 7 surveys also included questions regarding sunny vacations last 8 124	
weeks (“yes”/”no”) and use of solarium or any form of light therapy during the last 7 days 125	
(“weekly”/”sometimes”/”never”). However, only 30 % of the subjects answered these 126	
questions in Tromsø 6 and sunny vacation/use of solarium therefore not included in the 127	
tracking analyses.	 128	
     Height and weight were measured with light clothing, and body mass index (BMI) 129	
calculated as kg/m2. Blood pressure was measured after a 2 min seated rest (in Tromsø 4 with 130	
Dinamap Vital Signs Monitor, Critikon Inc, Tampa, FL, USA; in Tromsø 6 and 7 with 131	
Dinamap ProCare 300 monitor, GE Healthcare, Oslo, Norway). The mean of the two last 132	
measurements was used in our analyses.  133	
     Blood samples were non-fasting. Serum cholesterol and serum calcium were analyzed as 134	
previously described [24, 25]. These methods have a total analytic coefficient of variation 135	
(CV) of < 2 % and 2.5 %, respectively. 136	
     The samples from Tromsø 4 were stored at -70 degrees C and together with the samples 137	
from Tromsø 6 analyzed for 25(OH)D in batch with ECLIA (Roche) using an automated 138	
clinical chemistry analyzer (Modular E170, Roche Diagnostics). This method, which 139	
overestimates serum 25(OH)D in smokers has been described in detail previously and has a 140	
CV of 7.3 % (26). The samples from Tromsø 7 were analysed consecutively with an in-house 141	






Only subjects with valid serum 25(OH)D measurements in all three surveys were included in 146	
the analyses. The effect of season was adjusted for by calculating month specific z-scores for 147	
serum 25(OH)D for each survey. Since the assay used in Tromsø 4 and Tromsø 6 148	
overestimates serum 25(OH)D in smokers, the z-scores were calculated separately for 149	
smokers and non-smokers in all three surveys. Z-scores for smokers and non-smokers were 150	
then combined in the tracking analyses. We excluded subjects who changed smoking status 151	
between the surveys. 152	
     Normal distribution was evaluated with visual inspection of histograms and plots, and by 153	
assessing kurtosis and skewness. Distribution was normal for the dependent variables BMI, 154	
systolic blood pressure, serum calcium, serum cholesterol and serum 25(OH)D. The dataset 155	
was assessed using the Pitman-Morgan test for related samples, displaying homogeneity of 156	
variances. 157	
     Tracking was evaluated by Pearson’s correlation coefficient r. Blood pressure and 158	
cholesterol analyses only included subjects not using blood pressure or lipid medication, 159	
respectively. A linear regression model was used to evaluate predictors of serum 25(OH)D 160	
and of change in serum 25(OH)D z-score (delta z-score: z-score in Tromsø 7 minus z-score in 161	
Tromsø 4) with covariates as appears in the tables. In addition, the 25(OH)D z-scores from 162	
Tromsø 4 and 7 were divided into sextiles and cross-tabled to illustrate degree of tracking.   163	
     P < 0.05 (two-tailed) is considered statically significant. Data are presented as mean (SD) 164	
for normally distributed values, and as median (5th, 95th percentiles) for non-normally 165	






The Tromsø Study is approved by the Regional Committee for Medical Research Ethics 170	
(REK) and this investigation is covered by this approval. All included subjects signed a 171	




A total of 1,702 subjects (572 males, 1,130 females) with valid 25(OH)D measurements in the 176	
Tromsø 4, 6 and 7 surveys, and without change in smoking status were included in the present 177	
study. Their mean (SD) serum 25(OH)D levels were 57 (18) nmol/L, 59 (19) nmol/L and 72 178	
(21) nmol/L for Tromsø 4, Tromsø 6, and Tromsø 7, respectively. As expected, the serum 179	
25(OH)D levels were higher during the summer months, as shown for Tromsø 6 in Figure 1. 180	
Other characteristics from the separate surveys are displayed in Table 1.  181	
     In a linear regression model, sex, age, BMI, recent sunny vacation, intakes of cod liver oil 182	
and vitamin D supplements were significant predictors of serum 25(OH)D (Table 2).  183	
     The correlation coefficient r between serum 25(OH)D z-scores from Tromsø 4 and Tromsø 184	
6 was 0.40, and declined to 0.29 for the correlation between Tromsø 4 and Tromsø 7 (Table 185	
3). In comparison, correlations between Tromsø 4 – Tromsø 7 for BMI, systolic blood 186	
pressure (in subjects not using blood pressure medication), serum calcium and serum total 187	
cholesterol (in subjects not using lipid lowering medication) were slightly higher, at 0.78, 188	
0.45, 0.31 and 0.53, respectively (Table 3). The degree of tracking for serum 25(OH)D was 189	
higher in males, non-smokers, age > 55 years in Tromsø 4, change in BMI < 1.1 kg /m2, and 190	
with continuous use of cod liver oil or vitamin D supplements (Table 4).  191	
     The importance of BMI, use of cold liver oil, and vitamin D supplements for tracking of 192	
serum 25(OH)D was confirmed in a linear regression model where change in BMI and change 193	
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in intakes of vitamin D were significant predictors of change in serum 25(OH)D z-scores 194	
(Table 5). 195	
     To explore reasons for the higher tracking for serum 25(OH)D for males and for subjects > 196	
55 years, the serum 25(OH)D, BMI, intakes of cod liver oil and vitamin D supplement in 197	
relation to sex and age are shown for the three surveys in Table 6. In the females there was an 198	
increase in use of vitamin D supplementation from 8 % in Tromsø 4 to 29 % in Tromsø 7, 199	
whereas in the males the corresponding increase was only from 3 to 14 %. This could possibly 200	
explain the higher tracking in the males. However, there was in our data no obvious 201	
explanation for the higher tracking of serum 25(OH)D in  those with age > 55 years.  202	
     To further illustrate the degree of tracking, the change in distribution of sextiles of 203	
25(OH)D z-scores from Tromsø 4 to Tromsø 7 is shown in Table 7. Among those in the 204	
lowest sextile in Tromsø 4, 74 % were still in the three lowest sextiles of 25(OH)D in Tromsø 205	
7, but accordingly, 26 % had shifted to the three highest percentiles. Similarly, among those in 206	
the highest sextile in Tromsø 4, 65 % were still in the three highest sextiles in Tromsø 7, and 207	




In the present study, based on data from three surveys in the Tromsø study, we have found 212	
significant tracking of serum 25(OH)D over a 21-years period. Tracking was observed in both 213	
sexes, and in all age groups, with a correlation coefficient r ranging from 0.25 to 0.40 in the 214	
various subgroups between the first and last serum 25(OH)D measurement.  215	
     As expected, the degree of tracking declined over time. The correlation coefficient r was 216	
for all subjects 0.40 between the fourth and the sixth surveys (13 years apart), and dropped to 217	
0.29 between the forth and the seventh surveys (21 years apart). In comparison, one year 218	
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tracking data for participants receiving placebo in a vitamin D intervention study was as high 219	
as 0.80 [8].  220	
     When dividing the cohort into serum 25(OH)D z-score sextiles in the fourth and seventh 221	
surveys, 26 % of those in the lowest sextile in Tromsø 4 were in the upper half of the cohort 222	
in Tromsø 7. Conversely, 35 % of those in the highest sextile in Tromsø 4, were in the lower 223	
half in Tromsø 7. Consequently, the use of a single serum 25(OH)D measurement as an 224	
indicator of the vitamin D status, as has been frequently done in case-control studies [28, 29], 225	
appears to be highly questionable, at least if the observation time is long. Likewise, in 226	
prospective studies lasting for more than a few years, repeated measurements of serum 227	
25(OH)D should be used for estimation of vitamin D status before occurrence of the outcome 228	
in question. Furthermore, the high degree of tracking for serum 25(OH)D over shorter periods 229	
of time, like a few years, is an argument against repeated serum 25(OH)D measurements in 230	
clinical practice.   231	
     The serum 25(OH)D level is partly genetically determined, and several single nucleotide 232	
polymorphisms (SNPs) in enzymes necessary for production, transport and degradation of the 233	
active vitamin D metabolite 1,25-dihydroxyvitamin D have been described [6, 30]. These 234	
genetic differences may account for a large part of the variation in serum 25(OH)D levels [7]. 235	
However, the main determinants of serum 25(OH)D levels are amendable factors related to 236	
life-style, like time spent in the sun, intake of vitamin D rich food like fatty fish, and the use 237	
of vitamin D supplement [1, 30]. Furthermore, it appears as body size, in particular adipose 238	
tissue, is of importance by increasing volume of distribution [31]. It was therefore no surprise 239	
that tracking was more pronounced in subjects who continuously used cod liver oil and /or 240	
vitamin D supplements, and that changes in intake of these substances, as well as change in 241	
BMI, were associated with greater change in delta serum 25(OH)D z-scores. In Norway, 242	
which does not receive as much UV light during the summer as countries further south, the 243	
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importance of these factors are perhaps more important for 25(OH)D tracking than seasonal 244	
changes which are more pronounced in countries like England [32]. We also found a lower 245	
degree of tracking for serum 25(OH)D in the females, which could possibly be explained by 246	
an increase in their use of vitamin D supplements.  247	
     In addition to lifestyle factors, the degree of tracking is also influenced by the precision of 248	
the laboratory analyses, and for serum 25(OH)D the CV was higher than for serum calcium 249	
and total cholesterol. It should be noted that the tracking of serum 25(OH)D was lower than 250	
that found for serum calcium and serum total cholesterol, as well as for BMI and systolic 251	
blood pressure. For observational studies that rely on a single measurement these variables are 252	
therefore probably better suited than serum 25(OH)D.  253	
     In general, other studies have found a similar degree of tracking for serum 25(OH)D as we 254	
have [11, 17, 18, 20]. However, most of these studies have been of short duration, and to our 255	
knowledge, ours is the longest running by far. Some of these studies have included subjects in 256	
certain age groups or in particular periods of life. Thus, Thordisdottir et al. found in a group 257	
of 139 children a correlation coefficient between serum 25(OH)D at age 1 and 6 years of 0.34 258	
[17]. Similarly, Zhu et al. found in a group of 821 children with serum 25(OH)D measured at 259	
ages 6, 14, 17 and 20 years, correlation coefficients ranging from 0.35 to 0.56 depending on 260	
time interval [20]. On the other hand, Poopedi et al. found no significant correlation for 261	
25(OH)D between age 11 and 20 years in a group of 76 adolescents (r = 0.15), whereas 262	
between ages 15 and 20 the correlation was highly significant (r = 0.65) [18]. And finally, in 263	
1,753 pregnant women, Moon et al. found a correlation coefficient of 0.53 between season 264	
corrected serum 25(OH)D measurements at 11 and 34 weeks of gestation [11].  265	
     The mean serum 25(OH)D levels were similar in Tromsø 4 and Tromsø 6 which were 13 266	
years apart, but in Tromsø 7 eight years later the serum 25(OH)D was ~ 20 % higher. There 267	
was a change in 25(OH)D assay from Tromsø 6 to Tromsø 7, and in view of the time line, this 268	
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is the most likely explanation for the apparent increase in serum 25(OH)D. Additional factors 269	
could be the increase in use of daily vitamin D supplements from 7 to 24 % from Tromsø 4 to 270	
Tromsø 7, as well as nutritional changes that were not recorded in our study. Sunny vacation 271	
the last two months was a strong predictor of the serum 25(OH)D level in Tromsø 7, but was 272	
not asked for in the Tromsø 4 survey. Most likely such vacations were more frequent in 273	
2015/2016 than in 1994/1995 and could thus have contributed to the apparent increase in 274	
serum 25(OH)D in this cohort.  275	
     Our study has several weaknesses. In Tromsø 7 we used an LC-MS/MS assay for 276	
determination of serum 25(OH)D levels, whereas in Tromsø 4 and 6 an immunological assay 277	
was used. We could therefore not relate the degree of tracking to changes in nmol/L of serum 278	
25(OH)D, but had to make a z-score transformation. The assay used in Tromsø 4 and Tromsø 279	
6 overestimated serum 25(OH)D in smokers. We therefore calculated z-scores separately for 280	
smokers and non-smokers, before combining them into one group. Since we made month-281	
specific z-scores to adjust for seasonal variation, some of the smoker-groups became small, 282	
which can have made these z-scores less accurate. We had limited information regarding 283	
intakes of vitamin D, as well as sun-exposure, which could have improved the analysis of 284	
factors affecting the degree of tracking. The questionnaires regarding cod liver oil and vitamin 285	
D supplements differed slightly between the surveys and made evaluation of changes in these 286	
intakes difficult. We had to exclude subjects with change in smoking habits, which might 287	
have resulted in an overestimation of the serum 25(OH)D tracking. Only subjects who lived in 288	
Tromsø at all three time points could be included, and in societies with a high degree of 289	
mobility the tracking of serum 25(OH)D is likely to be lower. On the other hand, our study 290	
also has strengths as it was performed on the general population, included a large number of 291	
subjects of both sexes and of different ages, and the follow-up period was 21 years.  292	
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     In conclusion, we have found a significant degree of tracking for serum 25(OH)D over a 293	
period of 21 years. However, the degree of tracking declined over time, and using a single 294	
serum 25(OH)D measurement as an indicator of vitamin D status in long-term observational 295	
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January, 2 = February etc.) in the 1702 subjects in the sixth survey of the Tromsø study. No 420	
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